Vantictumab - Bayer HealthCare Pharmaceuticals/OncoMed Pharmaceuticals

Drug Profile

Vantictumab - Bayer HealthCare Pharmaceuticals/OncoMed Pharmaceuticals

Alternative Names: Anti-frizzled receptor monoclonal antibody - OncoMed; Anti-Fzd receptor monoclonal antibody - OncoMed; anti-Fzd7; Anti-Fzd7 receptor monoclonal antibody - OncoMed; OMP-18R5; Vantictumab

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
  • Developer OncoMed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Frizzled-receptor-antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Non-small cell lung cancer; Pancreatic cancer

Highest Development Phases

  • Suspended Breast cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 01 Jun 2017 OncoMed Pharmaceuticals completes a phase I trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, Recurrent) in USA (NCT01957007)
  • 08 May 2017 OncoMed Pharmaceuticals suspends patient enrolment in a phase I trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, Recurrent) in USA following a recent bone adverse event that occurred in a patient receiving vantictumab plus paclitaxel in a phase Ib HER2-negative breast cancer trial (IV)
  • 08 May 2017 OncoMed Pharmaceuticals suspends patient enrolment in a phase I trial in Pancreatic cancer (First-line combination therapy, Late-stage disease) in USA following a recent bone adverse event that occurred in a patient receiving vantictumab plus paclitaxel in a phase Ib HER2-negative breast cancer trial (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top